FIELD: biotechnology.
SUBSTANCE: group of inventions relates to a method of purifying antibodies from impurities, such as antibody degradation products. A method of purifying an anti-BCMA/anti-CD3 bispecific antibody is proposed. The antibody preparation is injected into the loading buffer onto the hydroxyapatite (HA) resin. The antibody preparation contains an intact bispecific antibody of interest with at least one type of impurity. Wash the resin with a wash buffer containing phosphate ions at a concentration of 10 to 50 mM. Elute the intact bispecific antibody of interest from the HA resin using an elution buffer containing phosphate ions at a concentration of 40 to 100 mM. The concentration of phosphate ions is increased compared to the wash buffer so that the bispecific antibody of interest is separated from at least one type of contaminant. The pH of the loading buffer, wash buffer and/or elution buffer is between pH 7.0 and 8.0. The resulting anti-BCMA/anti-CD3 bispecific antibody preparation contains not more than 1% of trimmed bispecific antibody as an impurity.
EFFECT: obtaining a method of antibody purification.
13 cl, 7 dwg, 5 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
CD3 BINDING ANTIBODIES | 2017 |
|
RU2807216C2 |
ANTIBODIES BINDING CD3 | 2017 |
|
RU2790288C2 |
BISPECIFIC ANTIBODY AND ITS USE | 2019 |
|
RU2785292C2 |
ANTIBODIES BINDING CD3 | 2017 |
|
RU2779489C2 |
BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-T CELLS | 2020 |
|
RU2762942C1 |
HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-NK-CELLS | 2020 |
|
RU2795443C2 |
MOLECULES THAT BIND BCMA AND USE OF SUCH MOLECULES | 2019 |
|
RU2812322C2 |
ANTIBODIES AGAINST GUCY2c AND THEIR USE | 2019 |
|
RU2812113C2 |
Authors
Dates
2024-01-24—Published
2019-02-25—Filed